"Poly I-C" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Interferon inducer consisting of a synthetic, mismatched double-stranded RNA. The polymer is made of one strand each of polyinosinic acid and polycytidylic acid.
| Descriptor ID |
D011070
|
| MeSH Number(s) |
D13.695.578.550.560.600 D13.695.578.550.650.600
|
| Concept/Terms |
Poly I-C- Poly I-C
- Poly I C
- Poly(I-C)
- Polyriboinosinic-Polyribocytidylic Acid
- Polyriboinosinic Polyribocytidylic Acid
- Polyribose Inosin-Cytidil
- Inosin-Cytidil, Polyribose
- Polyribose Inosin Cytidil
- Poly(rI).Poly(rC)
- Polyinosinic-Polycytidylic Acid
- Polyinosinic Polycytidylic Acid
- Polyinosinic-Polycytidylic Acid (High MW)
|
Below are MeSH descriptors whose meaning is more general than "Poly I-C".
Below are MeSH descriptors whose meaning is more specific than "Poly I-C".
This graph shows the total number of publications written about "Poly I-C" by people in this website by year, and whether "Poly I-C" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 4 | 4 |
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 0 | 6 | 6 |
| 2010 | 1 | 3 | 4 |
| 2011 | 1 | 3 | 4 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 3 | 3 |
| 2014 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly I-C" by people in Profiles.
-
Arowosegbe A, Guo Z, Vanderleeden E, Derr AG, Wang JP. Janus kinase inhibition prevents autoimmune diabetes in LEW.1WR1 rats. J Autoimmun. 2025 Feb; 151:103358.
-
Marques RF, Gimenez AM, Caballero O, Simpson A, Salazar AM, Amino R, Godin S, Gazzinelli RT, Soares IS. Non-clinical toxicity and immunogenicity evaluation of a Plasmodium vivax malaria vaccine using Poly-ICLC (Hiltonol?) as adjuvant. Vaccine. 2024 Apr 02; 42(9):2394-2406.
-
Chen Y, Lei X, Jiang Z, Fitzgerald KA. Cellular nucleic acid-binding protein is essential for type I interferon-mediated immunity to RNA virus infection. Proc Natl Acad Sci U S A. 2021 06 29; 118(26).
-
Muralidharan S, Lim A, Catalano D, Mandrekar P. Human Binge Alcohol Intake Inhibits TLR4-MyD88 and TLR4-TRIF Responses but Not the TLR3-TRIF Pathway: HspA1A and PP1 Play Selective Regulatory Roles. J Immunol. 2018 04 01; 200(7):2291-2303.
-
Urban SL, Berg LJ, Welsh RM. Type 1 interferon licenses na?ve CD8 T cells to mediate anti-viral cytotoxicity. Virology. 2016 06; 493:52-9.
-
Urban SL, Welsh RM. Out-of-sequence signal 3 as a mechanism for virus-induced immune suppression of CD8 T cell responses. PLoS Pathog. 2014 Sep; 10(9):e1004357.
-
Polykratis A, Hermance N, Zelic M, Roderick J, Kim C, Van TM, Lee TH, Chan FKM, Pasparakis M, Kelliher MA. Cutting edge: RIPK1 Kinase inactive mice are viable and protected from TNF-induced necroptosis in vivo. J Immunol. 2014 Aug 15; 193(4):1539-1543.
-
Wochal P, Rathinam VA, Dunne A, Carlson T, Kuang W, Seidl KJ, Hall JP, Lin LL, Collins M, Schattgen SA, MacKay CR, Fagundes CT, Carpenter S, Fitzgerald KA, O'Neill LA. TRIL is involved in cytokine production in the brain following Escherichia coli infection. J Immunol. 2014 Aug 15; 193(4):1911-9.
-
Alkanani AK, Hara N, Lien E, Ir D, Kotter CV, Robertson CE, Wagner BD, Frank DN, Zipris D. Induction of diabetes in the RIP-B7.1 mouse model is critically dependent on TLR3 and MyD88 pathways and is associated with alterations in the intestinal microbiome. Diabetes. 2014 Feb; 63(2):619-31.
-
Eberwine RA, Cort L, Habib M, Mordes JP, Blankenhorn EP. Autoantigen-induced focusing of V?13+ T cells precedes onset of autoimmune diabetes in the LEW.1WR1 rat. Diabetes. 2014 Feb; 63(2):596-604.